About: Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in North Brunswick, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Latest price: $14.70 (-5.25%)
ANLNASDAQAdlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd. American Depositary Shares share price
ANL price activity
Last Price
$14.700
Change (24hr)
-0.82 USD (-5.25%)
Volume
161.83K
Volume (4w avg)
-
Open
$15.44
Day Range
$14.42 - $15.94
Previous Close
$15.51
Last Trade
09 Sep, 8:00 pm GMT+0
Delayed
09 Sep, 8:00 pm GMT+0
ANL price performance
Delayed
09 Sep, 8:00 pm GMT+0
ANL Market Signals